Expression of BRCA1 and BRCA2 Genes in Patients Undergoing Transrectal Prostate Biopsy

Authors

  • Eduardo Maciel Narvaes Universidade Federal de Rondonópolis (UFR), Faculdade de Ciências da Saúde. Rondonópolis (MT), Brasil. https://orcid.org/0009-0002-0950-4734
  • Alyna Araújo e Marcondes Universidade Federal de Rondonópolis (UFR), Faculdade de Ciências da Saúde. Rondonópolis (MT), Brasil. https://orcid.org/0000-0001-7930-9673
  • Roberto de Andrade Garcia Filho Universidade Federal de Rondonópolis (UFR), Faculdade de Ciências da Saúde. Rondonópolis (MT), Brasil. https://orcid.org/0000-0001-9403-2457
  • Paulo Gabriel da Silva Mota Universidade Federal de Rondonópolis (UFR), Faculdade de Ciências da Saúde. Rondonópolis (MT), Brasil. https://orcid.org/0000-0003-1614-7907
  • Patricia de Lima Lemos Universidade Federal de Rondonópolis (UFR), Faculdade de Ciências da Saúde. Rondonópolis (MT), Brasil. https://orcid.org/0000-0002-5956-4471
  • Claudinéia de Araújo Universidade Federal de Rondonópolis (UFR), Faculdade de Ciências da Saúde. Rondonópolis (MT), Brasil. https://orcid.org/0000-0002-3043-2731

DOI:

https://doi.org/10.32635/2176-9745.RBC.2026v72n1.5460

Keywords:

Prostatic Neoplasms/pathology, Genes, BRCA1, Genes, BRCA2, Gene Expression, Neoplasm Grading/statistics & numerical data

Abstract

Introduction: Prostate cancer (PCa) is the second most common type of cancer among the male population. Men carrying mutations in the BRCA1 and BRCA2 genes are known to have a greater risk of developing PCa. Objective: To correlate clinical and anatomopathological aspects with the expression of the BRCA1 and BRCA2 genes in patients who underwent transrectal prostate biopsy. Method: Transrectal prostate biopsy fragments were collected from 89 individuals. Samples from 84 patients were subjected to RT‒qPCR to evaluate the expression of BRCA1 and BRCA2 transcripts. Results: Of the 84 selected patients, 26 (30.90%) tested positive for PCa and had a PSA level > 10 ng/ml (p=0.019). The median expression of the BRCA1 and BRCA2 genes in negative fragments was greater in PCa-positive patients (p=0.002 and p=0.038, respectively). BRCA1 gene expression was greater in PCa-negative patients than in patients with PCa (p=0.003). There was no statistically significant difference in the expression of the BRCA1 and BRCA2 genes according to Gleason classification or PSA values. Conclusion: The results demonstrated that the median expression of the BRCA1 and BRCA2 genes was greater in negative fragments from patients with prostate cancer than in fragments from individuals without prostate cancer.

Downloads

Download data is not yet available.

References

Instituto Nacional de Câncer. Estimativa 2023: incidência de câncer no Brasil [Internet]. Rio de Janeiro: INCA; 2022 [acesso 2023 out 24]. 160 p. Disponível em: https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-2023.pdf

Taitt HE. Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. Am J Mens Health. 2018;12(6):1807-23. DOI: https://doi.org/10.1177/1557988318798279

Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149(4):778-89. doi: https://doi.org/10.1002/ijc.33588 DOI: https://doi.org/10.1002/ijc.33588

Freitas CSM, Soares AN. Efficacy of leuprorelide acetate (Eligard®) in daily practice in Brazil: a retrospective study with depot formulations in patients with prostate cancer. Int braz j urol. 2020;46:383-9. doi: https://www.doi.org/10.1590/S1677-5538.IBJU.2019.0212 DOI: https://doi.org/10.1590/s1677-5538.ibju.2019.0212

Nicolosi P, Ledet E, Yang S, et al. Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines. JAMA Oncol. 2019;5(4):523-8. doi: https://doi.org/10.1001/jamaoncol.2018.6760 DOI: https://doi.org/10.1001/jamaoncol.2018.6760

Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402-16. doi: https://doi.org/10.1001/jama.2017.7112 DOI: https://doi.org/10.1001/jama.2017.7112

Nyberg T, Frost D, Barrowdale D, et al. Riscos de câncer de próstata em homens com BRCA1e portadores de mutação BRCA2: um estudo de coorte prospectivo. Eur Urol. 2020;77(1):24-35. doi: https://doi.org/10.1016/j.eururo.2019.08.025 DOI: https://doi.org/10.1016/j.eururo.2019.08.025

Stopsack KH, Gerke T, Zareba P, et al. Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer. Carcinogenesis. 2020;41(7):904-8. doi: https://doi.org/10.1093/carcin/bgaa061 DOI: https://doi.org/10.1093/carcin/bgaa061

Oh H, Lee YJ, Kang SG, et al. BRCA1-associated protein 1 expression and prognostic role in prostate adenocarcinoma. Investig Clin Urol. 2020;61(2):166-72. doi: https://doi.org/10.4111/icu.2020.61.2.166 DOI: https://doi.org/10.4111/icu.2020.61.2.166

Patel VL, Busch EL, Friebel TM, et al. Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness. Cancer Res. 2020;80(3):624-38. DOI: https://doi.org/10.1158/0008-5472.CAN-19-1840

Song WH, Kim SH, Joung JY, et al. Prostate cancer in a patient with a family history of brca mutation: a case report and literature review. J Korean Med Sci. 2017;32(2):377-81. DOI: https://doi.org/10.3346/jkms.2017.32.2.377

Schayek H, Haugk K, Sun S, et al. Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor i receptor (IGF-IR) gene transcription in an androgen receptor–dependent manner. Clin Cancer Res. 2009;15(5):1558-65. DOI: https://doi.org/10.1158/1078-0432.CCR-08-1440

Livak KJ, Schmittgen TD. Análise de dados de expressão gênica relativa usando PCR quantitativo em tempo real e o método 2 −ΔΔ CT. Methods. 2001;25(4):402-8. DOI: https://doi.org/10.1006/meth.2001.1262

StataR [Internet]. Versão 16.0. Lakeway: StataCorp LLC; 1996-2024c. [acesso 2025 jul 20]. Disponível em: https://www.stata.com/

Conselho Nacional de Saúde (BR). Resolução n° 466, de 12 de dezembro de 2012. Aprova as diretrizes e normas regulamentadoras de pesquisas envolvendo seres humanos. Diário Oficial da União, Brasília, DF. 2013 jun 13; Seção I:59.

Conselho Nacional de Saúde (BR). Resolução n° 510, de 7 de abril de 2016. Dispõe sobre as normas aplicáveis a pesquisas em Ciências Humanas e Sociais cujos procedimentos metodológicos envolvam a utilização de dados diretamente obtidos com os participantes ou de informações identificáveis ou que possam acarretar riscos maiores do que os existentes na vida cotidiana, na forma definida nesta Resolução [Internet]. Diário Oficial da União, Brasília, DF. 2016 maio 24 [acesso 2024 abr 7]; Seção 1:44. Disponível em: http://bvsms.saude.gov.br/bvs/saudelegis/cns/2016/res0510_07_04_2016.html

Segal N, Ber Y, Benjaminov O, et al. Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screening. Annals of Oncology. 2020;31(11):1545-52. DOI: https://doi.org/10.1016/j.annonc.2020.06.025

Rabiau N, Déchelotte P, Adjakly M, et al. BRCA1, BRCA2, AR and IGF-I expression in prostate cancer: correlation between RT-qPCR and immunohistochemical detection. Oncology Reports. 2011;26(3):695-702.

Ibrahim M, Yadav S, Ogunleye F, et al. Male BRCA mutation carriers: clinical characteristics and cancer spectrum. BMC Cancer. 2018;18(1):179. DOI: https://doi.org/10.1186/s12885-018-4098-y

Amirrad F, Pytak P, Sadeghiani‑Pelar N, et al. Prostate field cancerization and exosomes: association between CD9, early growth response 1 and fatty acid synthase. Int J Oncol [Internet]. 2020 [acesso 2025 out 11]; Disponível em: http://www.spandidos-publications.com/10.3892/ijo.2020.4980 DOI: https://doi.org/10.3892/ijo.2020.4980

Amsi PT, Yahaya JJ, Kalungi S, et al. Immunohistochemical expression of BRCA1 and BRCA2 in a cohort of Ugandan men with prostate cancer: an analytical cross-sectional study. Afr J Urol. 2020;26(1):71. DOI: https://doi.org/10.1186/s12301-020-00079-w

Evans DG, Burghel G, Schlecht H, et al. UK-based clinical testing programme for somatic and germline BRCA1/2, ATM and CDK12 mutations in prostate cancer: first results. bmjonc [Internet]. 2025 [acesso 2025 out 11];4(1). Disponível em: https://bmjoncology.bmj.com/content/4/1/e000592 DOI: https://doi.org/10.1136/bmjonc-2024-000592

Vatrano S, Pepe P, Pepe L, et al. BRCA mutations and prostate cancer: should urologist improve daily clinical practice? Arch Ital Urol Androl. 2025;97(2):13635. doi: https://doi.org/10.4081/aiua.2025.13635 DOI: https://doi.org/10.4081/aiua.2025.13635

Chen W, Xia W, Xue S, et al. Analysis of BRCA germline mutations in chinese prostate cancer patients. Front Oncol. 2022;12(746102):1-9. doi: https://doi.org/10.3389/fonc.2022.746102 DOI: https://doi.org/10.3389/fonc.2022.746102

Downloads

Published

2025-11-18

How to Cite

1.
Narvaes EM, Marcondes AA e, Garcia Filho R de A, Mota PG da S, Lemos P de L, Araújo C de. Expression of BRCA1 and BRCA2 Genes in Patients Undergoing Transrectal Prostate Biopsy. Rev. Bras. Cancerol. [Internet]. 2025 Nov. 18 [cited 2025 Dec. 4];72(1):e-185460. Available from: https://rbc.inca.gov.br/index.php/revista/article/view/5460

Issue

Vol. 72 No. 1 (2026): Jan./Feb./Mar.

Section

ORIGINAL ARTICLE

License

Os direitos morais e intelectuais dos artigos pertencem aos respectivos autores, que concedem à RBC o direito de publicação.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.